Trevi Therapeutics, Inc. (NasdaqGM: TRVI)
Health Care · Pharmaceuticals · US
$13.19
0.00% today · +33.0% 1Y
Trevi Therapeutics, Inc. (NasdaqGM: TRVI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.88B and employs 34 people.
Over the last twelve months the share price has gained 33.0%, trading between 9.28 and 20.22.
Tweenvest scores Trevi Therapeutics, Inc. across four factors: quality 48/100, value 76/100. Its strongest factor is value.
TRVI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.88B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.35
- Dividend yield
- —
- Beta (5Y)
- 0.98
- 52-week high
- $20.22
- 52-week low
- $9.28
- Avg volume (3M)
- —
- Shares outstanding
- 142.48M
- Employees
- 34
- Next earnings
- —
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
- ISIN
- US89532M1018
- Founded
- 2011
- Listed since
- May 7, 2019
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc.NasdaqGS: XERS | $1.91B | $10.41 | -0.72% |
| Shenyang Xingqi Pharmaceutical Co.,Ltd.SZSE: 300573 | $1.90B | CN¥35.55 | -0.31% |
| Porton Pharma Solutions Ltd.SZSE: 300363 | $1.90B | CN¥23.68 | -3.58% |
| The United Laboratories International Holdings LimitedSEHK: 3933 | $1.89B | HK$7.52 | +0.07% |
| Beijing Aosaikang Pharmaceutical Co., Ltd.SZSE: 002755 | $1.85B | CN¥13.34 | -1.55% |
| Structure Therapeutics Inc.NasdaqGM: GPCR | $1.82B | $24.74 | -3.15% |
| Pfizer LimitedNSEI: PFIZER | $1.80B | Rs3,808.20 | +1.55% |
| Septerna, Inc.NasdaqGM: SEPN | $1.79B | $37.96 | -1.07% |
Figures last refreshed Oct 11, 2026.